High-throughput screening technologies for botulinum neurotoxins

Current Topics in Medicinal Chemistry

Volumn 14, Issue 18, 2014, Pages 2062-2080

  Bompiani, Kristin M ^a   Dickerson, Tobin J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antibody; Antitoxin; Aptamer; Botulinum neurotoxin; Botulism; High throughput screening; Small molecule

Indexed keywords

APTAMER; BOTULINUM ANTISERUM; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN F; OLIGONUCLEOTIDE; SNARE PROTEIN; SYNAPTOBREVIN 2; ANTIDOTE; CHELATING AGENT; ENZYME INHIBITOR; MOLECULAR LIBRARY; NEUTRALIZING ANTIBODY; PEPTIDE LIBRARY; PEPTIDOMIMETIC AGENT;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOFLUORESCENCE; LIMIT OF DETECTION; MICROFLUIDICS; MOLECULAR DOCKING; NONHUMAN; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN INTERACTION; SURFACE PLASMON RESONANCE; TOXIN ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOTERRORISM; BOTULISM; CHEMISTRY; DEVICES; DRUG EFFECTS; MOLECULAR LIBRARY; MOTONEURON; PATHOLOGY; PHARMACOLOGY; PREVENTION AND CONTROL; PROCEDURES; SYNAPTIC TRANSMISSION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIDOTES; APTAMERS, NUCLEOTIDE; BIOTERRORISM; BOTULINUM TOXINS, TYPE A; BOTULISM; CHELATING AGENTS; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOTOR NEURONS; PEPTIDE LIBRARY; PEPTIDOMIMETICS; SMALL MOLECULE LIBRARIES; SYNAPTIC TRANSMISSION;

EID: 84926317388     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666141022093857     Document Type: Article

References (149)

1. Robinson, R.F.; Nahata, M.C. Management of botulism. Ann. Pharmacother., 2003, 37 (1), 127-31.
2. Simpson, L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 167-93.
3. Johnson, E.A. Clostridial toxins as therapeutic agents: benefits of nature’s most toxic proteins. Annu. Rev. Microbiol., 1999, 53, 551-75.
4. Arnon, S.S.; Schechter, R.; Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Fine, A.D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M.T.; O’Toole, T.; Parker, G.; Perl, T.M.; Russell, P. K.; Swerdlow, D. L.; Tonat, K. Botulinum toxin as a biological weapon: medical and public health management. JAMA, 2001, 285(8), 1059-70.
5. Council, U.N.S. Tenth report of the executive committee of the special commission established by the secretary-general pursuant to paragraph 9(b)(I) of security council resolution 687 (1991), and paragraph 3 of resolution 699 (1991) on the activities of the Special Commission. Council, U. N. S. Ed. New York, NY, 1995.
6. Zilinskas, R.A. Iraq’s biological weapons. The past as future? JAMA, 1997, 278(5), 418-24.
7. Darling, R.G.; Catlett, C.L.; Huebner, K.D.; Jarrett, D.G. Threats in bioterrorism. I: CDC category A agents. Emerg. Med. Clin. North. Am., 2002, 20 (2), 273-309.
8. Lacy, D.B.; Tepp, W.; Cohen, A.C.; DasGupta, B.R.; Stevens, R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol., 1998, 5(10), 898-902.
9. Binz, T.; Rummel, A. Cell entry strategy of clostridial neurotoxins. J. Neurochem., 2009, 109(6), 1584-95.
10. Hoch, D.H.; Romero-Mira, M.; Ehrlich, B.E.; Finkelstein, A.; DasGupta, B.R.; Simpson, L.L. Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes. Proc. Natl. Acad. Sci. U. S. A, 1985, 82(6), 1692-6.
11. Koriazova, L.K.; Montal, M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat. Struct. Biol., 2003, 10(1), 13-8.
12. Montal, M. Botulinum neurotoxin: a marvel of protein design. Annu. Rev. Biochem., 2010, 79, 591-617.
13. Barash, J.R.; Arnon, S.S. A Novel Strain of Clostridium botulinum. That Produces Type B and Type H Botulinum Toxins. J. Infect. Dis., 2013, 209(2), 183-91.
14. Dover, N.; Barash, J.R.; Hill, K.K.; Xie, G.; Arnon, S.S. Molecular Characterization of a Novel Botulinum Neurotoxin Type H Gene. J. Infect. Dis., 2013, 209(2), 192-202.
15. Lacy, D.B.; Stevens, R.C. Sequence homology and structural analysis of the clostridial neurotoxins. J. Mol. Biol., 1999, 291(5), 1091-104.
16. Binz, T.; Sikorra, S.; Mahrhold, S. Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering. Toxins (Basel), 2010, 2(4), 665-82.
17. Schantz, E.J.; Johnson, E.A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev., 1992, 56(1), 80-99.
18. Sloop, R.R.; Cole, B.A.; Escutin, R.O. Human response to botulinum toxin injection: type B compared with type A. Neurology, 1997, 49(1), 189-94.
19. Hill, K.K.; Smith, T.J. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr. Top. Microbiol. Immunol., 2013, 364, 1-20.
20. Brook, I. Botulism: the challenge of diagnosis and treatment. Rev. Neurol. Dis., 2006, 3(4), 182-9.
21. Byrne, M.P.; Smith, L.A. Development of vaccines for prevention of botulism. Biochimie., 2000, 82(9-10), 955-66.
22. Rusnak, J.M.; Smith, L.A. Botulinum neurotoxin vaccines: Past history and recent developments. Hum. Vaccin., 2009, 5(12), 794-805.
23. Keller, J.E.; Cai, F.; Neale, E.A. Uptake of botulinum neurotoxin into cultured neurons. Biochemistry (Mosc). 2004, 43(2), 526-32.
24. Deshpande, S.S.; Sheridan, R.E.; Adler, M. Efficacy of certain quinolines as pharmacological antagonists in botulinum neurotoxin poisoning. Toxicon, 1997, 35(3), 433-45.
25. Fischer, A.; Nakai, Y.; Eubanks, L.M.; Clancy, C.M.; Tepp, W.H.; Pellett, S.; Dickerson, T.J.; Johnson, E.A.; Janda, K.D.; Montal, M. Bimodal modulation of the botulinum neurotoxin proteinconducting channel. Proc. Natl. Acad. Sci. U. S. A, 2009, 106(5), 1330-5.
26. Willis, B.; Eubanks, L. M.; Dickerson, T. J.; Janda, K.D. The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison. Angew. Chem. Int. Ed. Engl., 2008, 47(44), 8360-79.
27. Dickerson, T.J.; Janda, K.D. The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication. ACS Chem. Biol., 2006, 1(6), 359-69.
28. Tsai, Y.C.; Maditz, R.; Kuo, C.L.; Fishman, P.S.; Shoemaker, C.B.; Oyler, G.A.; Weissman, A. M. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc. Natl. Acad. Sci. U. S. A, 2010, 107(38), 16554-9.
29. Kuo, C.L.; Oyler, G.A.; Shoemaker, C.B. Accelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination. PLoS One, 2011, 6(5), e20352.
30. Hatheway, C. In: Laboratory diagnosis of infectious diseases: principles and practice; Balows, A.; Hausler, W.; Ohashi, M.; Turano, M. Ed.; Springer-Verlag: New York, 1988; Vol. 1, pp. 111-133.
31. CDC. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR. Morb. Mortal. Wkly. Rep., 2010, 59(10), 299.
32. Arnon, S.S. Creation and development of the public service orphan drug Human Botulism Immune Globulin. Pediatrics, 2007, 119(4), 785-9.
33. Kozaki, S.; Kamata, Y.; Nagai, T.; Ogasawara, J.; Sakaguchi, G. The use of monoclonal antibodies to analyze the structure of Clostridium botulinum type E derivative toxin. Infect. Immun., 1986, 52(3), 786-91.
34. Bavari, S.; Pless, D.D.; Torres, E.R.; Lebeda, F.J.; Olson, M.A. Identifying the principal protective antigenic determinants of type A botulinum neurotoxin. Vaccine, 1998, 16(19), 1850-6.
35. Yang, G.H.; Kim, K.S.; Kim, H.W.; Jeong, S.T.; Huh, G.H.; Kim, J.C.; Jung, H.H. Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B. Toxicon, 2004, 44(1), 19-25.
36. Corbett, C.R.; Elias, M.D.; Simpson, L.L.; Yuan, X.Y.; Cassan, R.R.; Ballegeer, E.; Kabani, A.; Plummer, F.A.; Berry, J.D. Highthroughput homogeneous immunoassay readily identifies monoclonal antibody to serovariant clostridial neurotoxins. J. Immunol. Methods, 2007, 328(1-2), 128-38.
37. Amersdorfer, P.; Wong, C.; Chen, S.; Smith, T.; Deshpande, S.; Sheridan, R.; Finnern, R.; Marks, J.D. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect. Immun., 1997, 65(9), 3743-52.
38. Amersdorfer, P.; Wong, C.; Smith, T.; Chen, S.; Deshpande, S.; Sheridan, R.; Marks, J.D. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine, 2002, 20(11-12), 1640-8.
39. Razai, A.; Garcia-Rodriguez, C.; Lou, J.; Geren, I.N.; Forsyth, C.M.; Robles, Y.; Tsai, R.; Smith, T.J.; Smith, L.A.; Siegel, R.W.; Feldhaus, M.; Marks, J.D. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J. Mol. Biol., 2005, 351(1), 158-69.
40. Lou, J.; Geren, I.; Garcia-Rodriguez, C.; Forsyth, C.M.; Wen, W.; Knopp, K.; Brown, J.; Smith, T.; Smith, L.A.; Marks, J.D. Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Pro. Eng. Des. Sel., 2010, 23(4), 311-9.
41. Mah, D.C.; Hu, W.G.; Pon, J.K.; Masri, S.A.; Fulton, R.E.; Monette, P.L.; Nagata, L.P. Recombinant anti-botulinum neurotoxin A single-chain variable fragment antibody generated using a phage display system. Hybrid Hybridomics, 2003, 22(5), 277-83.
42. Zhou, H.; Zhou, B.; Pellett, S.; Johnson, E.A.; Janda, K.D. Selection and characterization of a human monoclonal neutralizing antibody for Clostridium Botulinum neurotoxin serotype B. Bioorg. Med. Chem. Lett., 2009, 19(3), 662-4.
43. Wesolowski, J.; Alzogaray, V.; Reyelt, J.; Unger, M.; Juarez, K.; Urrutia, M.; Cauerhff, A.; Danquah, W.; Rissiek, B.; Scheuplein, F.; Schwarz, N.; Adriouch, S.; Boyer, O.; Seman, M.; Licea, A.; Serreze, D.V.; Goldbaum, F.A.; Haag, F.; Koch-Nolte, F. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol., 2009, 198(3), 157-74.
44. Goldman, E.R.; Anderson, G.P.; Conway, J.; Sherwood, L.J.; Fech, M.; Vo, B.; Liu, J.L.; Hayhurst, A. Thermostable llama single domain antibodies for detection of botulinum A neurotoxin complex. Anal. Chem., 2008, 80(22), 8583-91.
45. Swain, M.D.; Anderson, G.P.; Zabetakis, D.; Bernstein, R.D.; Liu, J.L.; Sherwood, L.J.; Hayhurst, A.; Goldman, E.R. Llama-derived single-domain antibodies for the detection of botulinum A neurotoxin. Anal. Bioanal. Chem., 2010, 398(1), 339-48.
46. Tremblay, J.M.; Kuo, C.L.; Abeijon, C.; Sepulveda, J.; Oyler, G.; Hu, X.; Jin, M.M.; Shoemaker, C.B. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon, 2010, 56(6), 990-8.
47. Pires-Alves, M.; Ho, M.; Aberle, K.K.; Janda, K.D.; Wilson, B.A. Tandem fluorescent proteins as enhanced FRET-based substrates for botulinum neurotoxin activity. Toxicon, 2009, 53(4), 392-9.
48. Dong, J.; Thompson, A.A.; Fan, Y.; Lou, J.; Conrad, F.; Ho, M.; Pires-Alves, M.; Wilson, B.A.; Stevens, R.C.; Marks, J.D. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alphaexosite binding region. J. Mol. Biol., 2010, 397(4), 1106-18.
49. Bakherad, H.; Mousavi Gargari, S.L.; Rasooli, I.; Rajabibazl, M.; Mohammadi, M.; Ebrahimizadeh, W.; Safaee Ardakani, L.; Zare, H. In Vivo Neutralization of Botulinum Neurotoxins Serotype E with Heavy-chain Camelid Antibodies (VHH). Mol. Biotechnol., 2013, 55(2), 159-67.
50. Schmidt, J.J.; Stafford, R.G.; Bostian, K.A. Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1’ binding subsite. FEBS Lett., 1998, 435(1), 61-4.
51. Kumar, G.; Agarwal, R.; Swaminathan, S. Discovery of a fluorene class of compounds as inhibitors of botulinum neurotoxin serotype E by virtual screening. Chem. Commun. (Camb)., 2012, 48(18), 2412-4.
52. Schmidt, J.J.; Stafford, R.G. A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity. FEBS Lett., 2002, 532(3), 423-6.
53. Yiadom, K.P.; Muhie, S.; Yang, D.C. Peptide inhibitors of botulinum neurotoxin by mRNA display. Biochem. Biophys. Res. Commun., 2005, 335(4), 1247-53.
54. Zdanovskaia, M.V.; Los, G.; Zdanovsky, A.G. Recombinant derivatives of clostridial neurotoxins as delivery vehicles for proteins and small organic molecules. J. Protein Chem., 2000, 19(8), 699-707.
55. Ma, H.; Zhou, B.; Kim, Y.; Janda, K.D. A cyclic peptide-polymer probe for the detection of Clostridium botulinum neurotoxin serotype A. Toxicon, 2006, 47(8), 901-8.
56. Moore, G.J.; Moore, D.M.; Roy, S.S.; Hayden, L.J.; Hamilton, M.G.; Chan, N.W.; Lee, W.E. Hinge peptide combinatorial libraries for inhilbitors of botulinum neurotoxins and saxitoxin: deconvolution strategy. Mol. Divers., 2006, 10(1), 9-16.
57. Saunders, M.J.; Graves, S.W.; Sklar, L.A.; Oprea, T.I.; Edwards, B.S. High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. Assay Drug Dev. Technol., 2010, 8(1), 37-46.
58. Schmidt, J.J.; Stafford, R.G.; Millard, C.B. High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F. Anal. Biochem., 2001, 296(1), 130-7.
59. Schmidt, J.J.; Stafford, R.G. Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Appl. Environ. Microbiol., 2003, 69(1), 297-303.
60. Boldt, G.E.; Kennedy, J.P.; Hixon, M.S.; McAllister, L.A.; Barbieri, J.T.; Tzipori, S.; Janda, K.D. Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J. Comb. Chem., 2006, 8(4), 513-21.
61. Marconi, S.; Ferracci, G.; Berthomieu, M.; Kozaki, S.; Miquelis, R.; Boucraut, J.; Seagar, M.; Leveque, C. A protein chip membrane-capture assay for botulinum neurotoxin activity. Toxicol. Appl. Pharmacol., 2008, 233(3), 439-46.
62. Park, J.G.; Sill, P.C.; Makiyi, E.F.; Garcia-Sosa, A.T.; Millard, C.B.; Schmidt, J.J.; Pang, Y.P. Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A. Bioorg. Med. Chem., 2006, 14(2), 395-408.
63. Breidenbach, M.A.; Brunger, A.T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature, 2004, 432(7019), 925-9.
64. Segelke, B.; Knapp, M.; Kadkhodayan, S.; Balhorn, R.; Rupp, B. Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity. Proc. Natl. Acad. Sci. U. S. A, 2004,101(18), 6888-93.
65. Fu, Z.; Chen, S.; Baldwin, M.R.; Boldt, G.E.; Crawford, A.; Janda, K.D.; Barbieri, J.T.; Kim, J. J. Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate. Biochemistry (Mosc). 2006, 45(29), 8903-11.
66. Silvaggi, N.R.; Boldt, G.E.; Hixon, M.S.; Kennedy, J.P.; Tzipori, S.; Janda, K.D.; Allen, K.N. Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with smallmolecule inhibitors highlight active-site flexibility. Chem. Biol., 2007, 14(5), 533-42.
67. Thompson, A.A.; Jiao, G.S.; Kim, S.; Thai, A.; Cregar-Hernandez, L.; Margosiak, S.A.; Johnson, A.T.; Han, G.W.; O’Malley, S.; Stevens, R.C. Structural characterization of three novel hydroxamatebased zinc chelating inhibitors of the Clostridium botulinum serotype A neurotoxin light chain metalloprotease reveals a compact binding site resulting from 60/70 loop flexibility. Biochemistry (Mosc). 2011, 50(19), 4019-28.
68. Burnett, J.C.; Ruthel, G.; Stegmann, C.M.; Panchal, R.G.; Nguyen, T.L.; Hermone, A.R.; Stafford, R.G.; Lane, D.J.; Kenny, T.A.; McGrath, C.F.; Wipf, P.; Stahl, A.M.; Schmidt, J.J.; Gussio, R.; Brunger, A.T.; Bavari, S. Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J. Biol. Chem., 2007, 282(7), 5004-14.
69. Hermone, A.R.; Burnett, J.C.; Nuss, J.E.; Tressler, L.E.; Nguyen, T.L.; Solaja, B.A.; Vennerstrom, J.L.; Schmidt, J.J.; Wipf, P.; Bavari, S.; Gussio, R. Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore. Chem. Med. Chem., 2008, 3(12), 1905-12.
70. Roxas-Duncan, V.; Enyedy, I.; Montgomery, V.A.; Eccard, V.S.; Carrington, M.A.; Lai, H.; Gul, N.; Yang, D.C.; Smith, L.A. Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A. Antimicrob. Agents Chemother., 2009, 53(8), 3478-86.
71. Eichhorn, T.; Dolimbek, B.Z.; Deeg, K.; Efferth, T.; Atassi, M.Z. Inhibition in vivo of the activity of botulinum neurotoxin A by small molecules selected by virtual screening. Toxicon, 2012, 60(6), 1180-90.
72. Dadgar, S.; Ramjan, Z.; Floriano, W.B. Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A. J. Med. Chem., 2013, 56(7), 2791-803.
73. Arndt, J.W.; Chai, Q.; Christian, T.; Stevens, R.C. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity. Biochemistry (Mosc). 2006, 45(10), 3255-62.
74. Arndt, J.W.; Yu, W.; Bi, F.; Stevens, R.C. Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition. Biochemistry (Mosc). 2005, 44(28), 9574-80.
75. Agarwal, R.; Binz, T.; Swaminathan, S. Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design. Biochemistry (Mosc). 2005, 44(35), 11758-65.
76. Hanson, M.A.; Stevens, R.C. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution. Nat. Struct. Biol., 2000, 7(8), 687-92.
77. Jin, R.; Sikorra, S.; Stegmann, C.M.; Pich, A.; Binz, T.; Brunger, A.T. Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity. Biochemistry (Mosc). 2007, 46(37), 10685-93.
78. Schmidt, J.J.; Bostian, K.A. Proteolysis of synthetic peptides by type A botulinum neurotoxin. J. Protein Chem., 1995, 14(8), 703-8.
79. Shone, C.C.; Roberts, A.K. Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin. Eur. J. Biochem., 1994, 225(1), 263-70.
80. Burnett, J.C.; Schmidt, J.J.; Stafford, R.G.; Panchal, R.G.; Nguyen, T.L.; Hermone, A.R.; Vennerstrom, J.L.; McGrath, C.F.; Lane, D.J.; Sausville, E.A.; Zaharevitz, D.W.; Gussio, R.; Bavari, S. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem. Biophys. Res. Commun., 2003, 310(1), 84-93.
81. Zhang, J.H.; Chung, T.D.; Oldenburg, K.R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen, 1999,4(2), 67-73.
82. Hines, H.B.; Kim, A.D.; Stafford, R.G.; Badie, S.S.; Brueggeman, E.E.; Newman, D.J.; Schmidt, J.J. Use of a recombinant fluorescent substrate with cleavage sites for all botulinum neurotoxins in highthroughput screening of natural product extracts for inhibitors of serotypes A, B, and E. Appl. Environ. Microbiol., 2008,74(3), 653-9.
83. Luo, S.; Li, T.; Wang, Q.; Tian, R.; Liu, H.; Fang, H.; Chen, F.; Wang, H. Development of a fusion protein SNVP as substrate for assaying multi-serotype botulinum neurotoxins. Anal. Biochem., 2013.
84. Anne, C.; Cornille, F.; Lenoir, C.; Roques, B.P. High-throughput fluorogenic assay for determination of botulinum type B neurotoxin protease activity. Anal. Biochem., 2001, 291(2), 253-61.
85. Salzameda, N.T.; Barbieri, J.T.; Janda, K.D. Synthetic substrate for application in both high and low throughput assays for botulinum neurotoxin B protease inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(20), 5848-50.
86. Cardinale, S.C.; Butler, M.M.; Ruthel, G.; Nuss, J.E.; Wanner, L.M.; Li, B.; Pai, R.; Peet, N.P.; Bavari, S.; Bowlin, T.L. Novel Benzimidazole Inhibitors of Botulinum Neurotoxin/A Display Enzyme and Cell-Based Potency. J. Botulinum., 2011, 2(1), 16-29.
87. Eubanks, L.M.; Hixon, M.S.; Jin, W.; Hong, S.; Clancy, C.M.; Tepp, W.H.; Baldwin, M.R.; Malizio, C.J.; Goodnough, M.C.; Barbieri, J.T.; Johnson, E.A.; Boger, D.L.; Dickerson, T.J.; Janda, K.D. An in vitro and in vivo disconnect uncovered through highthroughput identification of botulinum neurotoxin A antagonists. Proc. Natl. Acad. Sci. U. S. A, 2007, 104(8), 2602-7.
88. Boldt, G.E.; Kennedy, J.P.; Janda, K.D. Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org. Lett., 2006, 8(8), 1729-32.
89. Eubanks, L.M.; Silhar, P.; Salzameda, N.T.; Zakhari, J.S.; Xiaochuan, F.; Barbieri, J.T.; Shoemaker, C.B.; Hixon, M.S.; Janda, K.D. Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease. ACS Med. Chem. Lett., 2010, 1(6), 268-272.
90. Capkova, K.; Hixon, M.S.; McAllister, L.A.; Janda, K.D. Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations. Chem. Commun. (Camb)., 2008, (30), 3525-7.
91. Cai, S.; Lindo, P.; Park, J.B.; Vasa, K.; Singh, B.R. The identification and biochemical characterization of drug-like compounds that inhibit botulinum neurotoxin serotype A endopeptidase activity. Toxicon, 2010, 55(4), 818-26.
92. Washbourne, P.; Pellizzari, R.; Baldini, G.; Wilson, M.C.; Montecucco, C. Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis. FEBS Lett., 1997,418(1-2), 1-5.
93. Ruge, D.R.; Dunning, F.M.; Piazza, T.M.; Molles, B.E.; Adler, M.; Zeytin, F.N.; Tucker, W.C. Detection of six serotypes of botulinum neurotoxin using fluorogenic reporters. Anal. Biochem., 2011, 411(2), 200-9.
94. Ouimet, T.; Duquesnoy, S.; Poras, H.; Fournie-Zaluski, M.C.; Roques, B.P. Comparison of Fluorigenic Peptide Substrates PL50, SNAPtide, and BoTest A/E for BoNT/A Detection and Quantification: Exosite Binding Confers High-Assay Sensitivity. J. Biomol. Screen., 2013, 18(6), 726-35.
95. Rowe, B.; Schmidt, J.J.; Smith, L.A.; Ahmed, S.A. Rapid product analysis and increased sensitivity for quantitative determinations of botulinum neurotoxin proteolytic activity. Anal. Biochem., 2010,396(2), 188-93.
96. Burnett, J.C.; Schmidt, J.J.; McGrath, C.F.; Nguyen, T.L.; Hermone, A.R.; Panchal, R.G.; Vennerstrom, J. L.; Kodukula, K.; Zaharevitz, D.W.; Gussio, R.; Bavari, S. Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding. Bioorg. Med. Chem., 2005, 13(2), 333-41.
97. Mizanur, R.M.; Frasca, V.; Swaminathan, S.; Bavari, S.; Webb, R.; Smith, L.A.; Ahmed, S.A. The C terminus of the catalytic domain of type a botulinum neurotoxin may facilitate product release from the active site. J. Biol. Chem., 2013, 288(33), 24223-33.
98. Silhar, P.; Lardy, M.A.; Hixon, M.S.; Shoemaker, C.B.; Barbieri, J.T.; Struss, A.K.; Lively, J.M.; Javor, S.; Janda, K.D. The Cterminus of Botulinum A Protease Has Profound and Unanticipated Kinetic Consequences Upon the Catalytic Cleft. ACS Med. Chem. Lett., 2013, 4(2), 283-287.
99. Dong, M.; Tepp, W.H.; Johnson, E.A.; Chapman, E.R. Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc. Natl. Acad. Sci. U. S. A, 2004, 101(41), 14701-6.
100. [100] Nuss, J.E.; Ruthel, G.; Tressler, L.E.; Wanner, L.M.; Torres-Melendez, E.; Hale, M.L.; Bavari, S. Development of cell-based assays to measure botulinum neurotoxin serotype A activity using cleavage-sensitive antibodies. J. Biomol. Screen, 2010, 15(1), 42-51.
101. [101] Kiris, E.; Nuss, J.E.; Burnett, J.C.; Kota, K.P.; Koh, D.C.; Wanner, L.M.; Torres-Melendez, E.; Gussio, R.; Tessarollo, L.; Bavari, S. Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery. Stem Cell Res., 2011, 6(3), 195-205.
102. [102] Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346(6287), 818-22.
103. [103] Wyatt, J.R.; Puglisi, J.D.; Tinoco, I. Jr. RNA folding: pseudoknots, loops and bulges. Bioessays, 1989, 11(4), 100-6.
104. [104] Jenison, R.D.; Gill, S.C.; Pardi, A.; Polisky, B. High-resolution molecular discrimination by RNA. Science, 1994, 263(5152), 1425-9.
105. [105] Buddai, S.K.; Layzer, J.M.; Lu, G.; Rusconi, C.P.; Sullenger, B.A.; Monroe, D.M.; Krishnaswamy, S. An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase. J. Biol. Chem., 2010, 285(8), 5212-23.
106. [106] Bompiani, K.M.; Monroe, D.M.; Church, F.C.; Sullenger, B.A. A high affinity, antidote-controllable prothrombin and thrombinbinding RNA aptamer inhibits thrombin generation and thrombin activity. J. Thromb. Haemost., 2012,10(5), 870-80.
107. [107] Sullenger, B.; Woodruff, R.; Monroe, D.M. Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction. J. Biol. Chem., 2012, 287(16), 12779-86.
108. [108] Bock, L.C.; Griffin, L.C.; Latham, J.A.; Vermaas, E.H.; Toole, J.J. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 1992, 355(6360), 564-6.
109. [109] Layzer, J.M.; Sullenger, B.A. Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. Oligonucleotides, 2007, 17(1), 1-11.
110. [110] Pestourie, C.; Cerchia, L.; Gombert, K.; Aissouni, Y.; Boulay, J.; De Franciscis, V.; Libri, D.; Tavitian, B.; Duconge, F. Comparison of different strategies to select aptamers against a transmembrane protein target. Oligonucleotides, 2006, 16(4), 323-35.
111. [111] Dollins, C.M.; Nair, S.; Boczkowski, D.; Lee, J.; Layzer, J.M.; Gilboa, E.; Sullenger, B.A. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem. Biol., 2008,15(7), 675-82.
112. [112] Klussmann, S. In: The aptamer handbook: functional oligonucleotides and their applications; Wiley-VCH: Weinheim, 2006; pp. 1-490.
113. [113] Long, S.B.; Long, M.B.; White, R.R.; Sullenger, B.A. Crystal structure of an RNA aptamer bound to thrombin. RNA, 2008, 14, 1-9.
114. [114] Huang, R.H.; Fremont, D.H.; Diener, J.L.; Schaub, R.G.; Sadler, J.E. A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1. Structure, 2009, 17(11), 1476-84.
115. [115] Keefe, A.D.; Cload, S.T. SELEX with modified nucleotides. Curr. Opin. Chem. Biol., 2008, 12(4), 448-56.
116. [116] Brody, E.N.; Gold, L. Aptamers as therapeutic and diagnostic agents. J. Biotechnol., 2000, 74(1), 5-13.
117. [117] Boomer, R.M.; Lewis, S.D.; Healy, J.M.; Kurz, M.; Wilson, C.; McCauley, T.G. Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues. Oligonucleotides, 2005, 15(3), 183-95.
118. [118] Healy, J.M.; Lewis, S.D.; Kurz, M.; Boomer, R.M.; Thompson, K.M.; Wilson, C.; McCauley, T.G. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res., 2004, 21(12), 2234-46.
119. [119] Group, T.E.S. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina, 2002, 22(2), 143-52.
120. [120] Gragoudas, E.S.; Adamis, A.P.; Cunningham, E.T. Jr.; Feinsod, M.; Guyer, D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med., 2004, 351(27), 2805-16.
121. [121] Cunningham, E.T. Jr.; Adamis, A.P.; Altaweel, M.; Aiello, L.P.; Bressler, N.M.; D’Amico, D.J.; Goldbaum, M.; Guyer, D.R.; Katz, B.; Patel, M.; Schwartz, S.D. A phase II randomized doublemasked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology, 2005,112(10), 1747-57.
122. [122] Fitzwater, T.; Polisky, B. A SELEX primer. Methods Enzymol., 1996, 267, 275-301.
123. [123] Nimjee, S.M.; Rusconi, C.P.; Sullenger, B.A. Aptamers: an emerging class of therapeutics. Annu. Rev. Med., 2005, 56, 555-83.
124. [124] Hjalmarsson, K.; Marcellaro, A.; Norlander, L. In: Aptamers: Future Tools for Diagnostics and Therapy.; Umea, Swedish Defence Research Agency: 2004.
125. [125] Bridonneau, P.; Chang, Y.F.; Buvoli, A.V.; O’Connell, D.; Parma, D. Site-directed selection of oligonucleotide antagonists by competitive elution. Antisense Nucleic Acid Drug Dev., 1999,9(1), 1-11.
126. [126] Ulrich, H.; Ippolito, J.E.; Pagan, O.R.; Eterovic, V.A.; Hann, R.M.; Shi, H.; Lis, J.T.; Eldefrawi, M.E.; Hess, G.P. In vitro selection of RNA molecules that displace cocaine from the membrane-bound nicotinic acetylcholine receptor. Proc. Natl. Acad. Sci. U. S. A., 1998, 95(24), 14051-6.
127. [127] Tok, J.B.; Fischer, N.O. Single microbead SELEX for efficient ssDNA aptamer generation against botulinum neurotoxin. Chem. Commun. (Camb)., 2008, (16), 1883-5.
128. [128] Fan, M.; McBurnett, S.R.; Andrews, C.J.; Allman, A.M.; Bruno, J.G.; Kiel, J.L. Aptamer selection express: a novel method for rapid single-step selection and sensing of aptamers. J. Biomol. Tech., 2008, 19(5), 311-9.
129. [129] Lou, X.; Qian, J.; Xiao, Y.; Viel, L.; Gerdon, A.E.; Lagally, E.T.; Atzberger, P.; Tarasow, T.M.; Heeger, A. J.; Soh, H.T. Micromagnetic selection of aptamers in microfluidic channels. Proc. Natl. Acad. Sci. U. S. A., 2009, 106(9), 2989-94.
130. [130] Chang, T.W.; Blank, M.; Janardhanan, P.; Singh, B.R.; Mello, C.; Blind, M.; Cai, S. In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxin. Biochem. Biophys. Res. Commun., 2010, 396(4), 854-60.
131. [131] Pieken, W.A.; Olsen, D.B.; Benseler, F.; Aurup, H.; Eckstein, F. Kinetic characterization of ribonuclease-resistant 2’-modified hammerhead ribozymes. Science, 1991, 253(5017), 314-7.
132. [132] Bruno, J.G.; Richarte, A.M.; Carrillo, M.P.; Edge, A. An aptamer beacon responsive to botulinum toxins. Biosens. Bioelectron., 2012, 31(1), 240-3.
133. [133] Hamaguchi, N.; Ellington, A.; Stanton, M. Aptamer beacons for the direct detection of proteins. Anal. Biochem., 2001, 294(2), 126-31.
134. [134] Nowakowski, A.; Wang, C.; Powers, D.B.; Amersdorfer, P.; Smith, T.J.; Montgomery, V.A.; Sheridan, R.; Blake, R.; Smith, L.A.; Marks, J.D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. U. S. A., 2002, 99(17), 11346-50.
135. [135] Smith, T.J.; Lou, J.; Geren, I.N.; Forsyth, C.M.; Tsai, R.; Laporte, S.L.; Tepp, W.H.; Bradshaw, M.; Johnson, E.A.; Smith, L.A.; Marks, J.D. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun., 2005, 73(9), 5450-7.
136. [136] Capek, P.; Dickerson, T.J. Sensing the deadliest toxin: technologies for botulinum neurotoxin detection. Toxins (Basel), 2010, 2(1), 24-53.
137. [137] Baldwin, M.R.; Bradshaw, M.; Johnson, E.A.; Barbieri, J.T. The Cterminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability. Protein Expr. Purif., 2004, 37(1), 187-95.
138. [138] Schmidt, J.J.; Bostian, K.A. Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin. J. Pro. Chem., 1997, 16(1), 19-26.
139. [139] Boldt, G.E.; Eubanks, L.M.; Janda, K.D. Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. Chem. Commun. (Camb)., 2006, (29), 3063-5.
140. [140] Silhar, P.; Silvaggi, N.R.; Pellett, S.; Capkova, K.; Johnson, E.A.; Allen, K.N.; Janda, K.D. Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: synthesis, crystallography, modeling, kinetic and cellular based studies. Bioorg. Med. Chem., 2013, 21(5), 1344-8.
141. [141] Ruthel, G.; Burnett, J.C.; Nuss, J.E.; Wanner, L.M.; Tressler, L.E.; Torres-Melendez, E.; Sandwick, S. J.; Retterer, C.J.; Bavari, S. Post-intoxication inhibition of botulinum neurotoxin serotype A within neurons by small-molecule, non-peptidic inhibitors. Toxins (Basel), 2011, 3(3), 207-17.
142. [142] Thyagarajan, B.; Potian, J.G.; Garcia, C.C.; Hognason, K.; Capkova, K.; Moe, S.T.; Jacobson, A.R.; Janda, K.D.; McArdle, J.J. Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions. Neuropharmacology, 2010, 58(8), 1189-98.
143. [143] Pang, Y.P.; Davis, J.; Wang, S.; Park, J.G.; Nambiar, M.P.; Schmidt, J.J.; Millard, C.B. Small molecules showing significant protection of mice against botulinum neurotoxin serotype A. PLoS One, 2010,5(4), e10129.
144. [144] Singh, P.; Singh, M.K.; Chaudhary, D.; Chauhan, V.; Bharadwaj, P.; Pandey, A.; Upadhyay, N.; Dhaked, R.K. Small-molecule quinolinol inhibitor identified provides protection against BoNT/A in mice. PLoS One, 2012, 7(10), e47110.
145. [145] Wei, F.; Ho, C.M. Aptamer-based electrochemical biosensor for Botulinum neurotoxin. Anal. Bioanal. Chem., 2009, 393(8), 1943-8.
146. [146] Hafner, M.; Vianini, E.; Albertoni, B.; Marchetti, L.; Grune, I.; Gloeckner, C.; Famulok, M. Displacement of protein-bound aptamers with small molecules screened by fluorescence polarization. Nat. Protoc., 2008, 3(4), 579-87.
147. [147] Yamazaki, S.; Tan, L.; Mayer, G.; Hartig, J.S.; Song, J.N.; Reuter, S.; Restle, T.; Laufer, S.D.; Grohmann, D.; Krausslich, H.G.; Bajorath, J.; Famulok, M. Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance. Chem. Biol., 2007, 14(7), 804-12.
148. [148] Green, L.S.; Bell, C.; Janjic, N. Aptamers as reagents for highthroughput screening. BioTechniques, 2001, 30(5), 1094-1110.
149. [149] Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res., 2003, 31(13), 3406-15.